Difference between revisions of "Idarubicin (Idamycin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information")
 
(26 intermediate revisions by 3 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Anthracycline analog of [[Daunorubicin (Cerubidine)]], binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA. In comparison to other anthracyclines, idarubicin lacks a methoxy group at position 4 of the anthracycline structure, which results in it having high lipophilicity and an increased rate of cellular uptake compared with other anthracyclines.<ref name="insert">[http://www.pfizer.com/files/products/uspi_idamycin.pdf Idarubicin (Idamycin) package insert]</ref><ref>[http://www.pfizer.com/files/products/uspi_idamycin_pfs.pdf Idarubicin Preservative-Free Solution (Idamycin PFS) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/idarubicin.pdf Idarubicin (Idamycin) package insert (locally hosted backup)]</ref><ref>[http://hemonc.org/docs/packageinsert/idarubicinPFS.pdf Idarubicin Preservative-Free Solution (Idamycin PFS) (locally hosted backup)]</ref>
+
Class/mechanism: Anthracycline analog of [[Daunorubicin (Cerubidine)]], binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA. In comparison to other anthracyclines, idarubicin lacks a methoxy group at position 4 of the anthracycline structure, which results in it having high lipophilicity and an increased rate of cellular uptake compared with other anthracyclines.<ref name="insert">[http://www.pfizer.com/files/products/uspi_idamycin.pdf Idarubicin (Idamycin) package insert]</ref><ref>[http://www.pfizer.com/files/products/uspi_idamycin_pfs.pdf Idarubicin Preservative-Free Solution (Idamycin PFS) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/idarubicin.pdf Idarubicin (Idamycin) package insert (locally hosted backup)]</ref><ref>[https://hemonc.org/docs/packageinsert/idarubicinPFS.pdf Idarubicin Preservative-Free Solution (Idamycin PFS) (locally hosted backup)]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: [[vesicant]]
 
<br>Extravasation: [[vesicant]]
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref>  
 +
 
 +
==Diseases for which it is used==
 +
*[[Acute lymphocytic leukemia]]
 +
*[[Acute myeloid leukemia]]
 +
*[[Acute promyelocytic leukemia]]
  
 
==Patient drug information==
 
==Patient drug information==
 +
*[http://www.pfizer.com/files/products/uspi_idamycin.pdf Idarubicin (Idamycin) package insert]<ref name="insert"></ref>
 
*[http://chemocare.com/bio/idarubicin.asp Idarubicin (Idamycin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/idarubicin.asp Idarubicin (Idamycin) patient drug information (Chemocare)]</ref>
 
*[http://chemocare.com/bio/idarubicin.asp Idarubicin (Idamycin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/idarubicin.asp Idarubicin (Idamycin) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/idarubicin-patient-drug-information Idarubicin (Idamycin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/idarubicin-patient-drug-information Idarubicin (Idamycin) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/idarubicin-patient-drug-information Idarubicin (Idamycin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/idarubicin-patient-drug-information Idarubicin (Idamycin) patient drug information (UpToDate)]</ref>
  
 +
==History of changes in FDA indication==
 +
* 1990-09-27: Initial FDA approval in combination with other approved antileukemic drugs for the treatment of [[Acute myeloid leukemia|acute myeloid leukemia (AML)]] in adults. ''(Based on L-19 Protocol, Mandelli et al. 1991, Vogler et al. 1992, Wiernik et al. 1992)''
 +
* 2014-12-04 (most recent label available on Drugs @ FDA): "in combination with other approved antileukemic drugs is indicated for the treatment of [[Acute myeloid leukemia|acute myeloid leukemia (AML)]] in adults. This includes French-American- British (FAB) classifications M1 through M7."
 +
==History of changes in EMA indication==
 +
*1989-11-29: EURD
 
==Also known as==
 
==Also known as==
−
Idamycin,    Idamycin PFS,    Idaru,    idarubicin comp,   idarubicin hydrochloride,   Ondarubin,   Zanedos,   Zavedose
+
*'''Generic names:''' idarubicin comp, idarubicin hydrochloride
 +
*'''Brand names:''' Idamycin, Idaru, Ondarubin, Zavedos, Zavedose
  
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drugs]]
 +
[[Category:Intravenous medications]]
 +
[[Category:Vesicant]]
 +
 +
[[Category:Anthracyclines]]
 +
[[Category:Topoisomerase II inhibitors]]
 +
 +
[[Category:B-cell acute lymphoblastic leukemia medications]]
 +
[[Category:Acute myeloid leukemia medications]]
 +
[[Category:Acute promyelocytic leukemia medications]]
 +
 +
[[Category:FDA approved in 1990]]
 +
[[Category:EMA approved in 1989]]

Latest revision as of 01:00, 29 June 2024

General information

Class/mechanism: Anthracycline analog of Daunorubicin (Cerubidine), binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA. In comparison to other anthracyclines, idarubicin lacks a methoxy group at position 4 of the anthracycline structure, which results in it having high lipophilicity and an increased rate of cellular uptake compared with other anthracyclines.[1][2][3][4]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1990-09-27: Initial FDA approval in combination with other approved antileukemic drugs for the treatment of acute myeloid leukemia (AML) in adults. (Based on L-19 Protocol, Mandelli et al. 1991, Vogler et al. 1992, Wiernik et al. 1992)
  • 2014-12-04 (most recent label available on Drugs @ FDA): "in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American- British (FAB) classifications M1 through M7."

History of changes in EMA indication

  • 1989-11-29: EURD

Also known as

  • Generic names: idarubicin comp, idarubicin hydrochloride
  • Brand names: Idamycin, Idaru, Ondarubin, Zavedos, Zavedose

References

  1. ↑ 1.0 1.1 1.2 Idarubicin (Idamycin) package insert
  2. ↑ Idarubicin Preservative-Free Solution (Idamycin PFS) package insert
  3. ↑ Idarubicin (Idamycin) package insert (locally hosted backup)
  4. ↑ Idarubicin Preservative-Free Solution (Idamycin PFS) (locally hosted backup)
  5. ↑ Idarubicin (Idamycin) patient drug information (Chemocare)
  6. ↑ Idarubicin (Idamycin) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Idarubicin_(Idamycin)&oldid=87274"